KOSDAQBiotech & Pharma372320

Curocell

₩21,150▼ 1.17%2026-11-18 close
Market Cap
₩322.1B
Turnover
₩300M
Volume
10K
Shares out.
15.2M
PER
—
PBR
5.0×
EPS
-₩3,566
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

After RIMQARTO approval, commercialization is tested amid losses

Curocell's RIMQARTO received approval in April 2026, but with no revenue recorded in 2025, operating losses and cash outflows continue, making reimbursement listing and indication expansion the next checkpoints.

  1. 1

    RIMQARTO received Korean marketing approval on April 29, 2026, making it the first domestically developed CAR-T therapy, and price negotiations for reimbursement are ongoing.

  2. 2

    The company posted losses for four consecutive years from 2022 to 2025, with a 2025 operating loss of KRW 36.3 billion and a net loss attributable to controlling shareholders of KRW 46.3 billion.

  3. 3

    The operating loss narrowed to KRW 7.74 billion in Q3 2026, below both the prior quarter and the year-earlier period, after widening to KRW 9.74 billion in Q2 2026.

  4. 4

    Total equity at the end of 2025 was KRW 5.03 billion against total liabilities of KRW 104.7 billion, a debt-to-equity ratio of 2,083.4%.

  5. 5

    Long-term follow-up data from the RIMQARTO Phase 2 trial are scheduled for presentation at the ASH annual meeting on December 12–15, 2026, and the company targets reimbursement listing within 2026.

02

Business structure

Curocell is a cell and gene therapy developer founded in 2016 that builds next-generation CAR-T therapies on its proprietary OVIS platform.

Its lead product is RIMQARTO (generic name anbalcabtagene autoleucel), an autologous CD19-targeted CAR-T therapy that received marketing approval from the Ministry of Food and Drug Safety on April 29, 2026, making it the first domestically developed CAR-T therapy in Korea.

The approved indication is relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients receiving third-line or later treatment. To expand the indication to second-line treatment, the company applied on October 30, 2026 for a change approval of its Phase 3 trial plan with the Ministry.

Production takes place at a CAR-T-dedicated commercial GMP facility in Daejeon, and the company says it can supply patients in Korea without relying on overseas manufacturing sites.

The revenue structure is still at an early stage, since RIMQARTO is set to launch fully after price negotiations and National Health Insurance listing.

The Korean CAR-T market has been dominated in practice by Novartis's Kymriah, which is manufactured overseas and has supply gaps that the company cites as its point of differentiation.

The pipeline includes a solid tumor CAR-T built on the Hyperkine technology, an in vivo CAR-T approach, and clinical studies in systemic lupus erythematosus and adult acute lymphoblastic leukemia (ALL). Overseas, the company plans to enter Japan and run investigator-led clinical studies in China in parallel.

Unlike many Korean biotech firms that rely on technology licensing, Curocell is pursuing direct commercialization.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩0-₩9.2B—
2025Q4₩0-₩8.7B—
2026Q1₩0-₩7.8B—
2026Q2₩0-₩9.7B—
2026Q3₩0-₩7.7B—
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩0-₩21.4B-₩38.9B——−284.9%
2023₩0-₩31.1B-₩29.6B—−50.0%77.6%
2024₩0-₩36.6B-₩38.2B—−129.8%144.5%
2025₩0-₩36.3B-₩46.3B—−921.5%2083.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a DART-disclosed basis, Curocell's operating loss widened from KRW 21.4 billion in 2022 to KRW 31.1 billion in 2023 and KRW 36.6 billion in 2024, then narrowed to KRW 36.3 billion in 2025. The company recorded losses for four consecutive years from 2022 to 2025.

The net loss attributable to controlling shareholders was KRW 38.9 billion in 2022, KRW 29.6 billion in 2023, KRW 38.2 billion in 2024, and KRW 46.3 billion in 2025, so the loss widened again in 2025.

The net loss including non-controlling interests was disclosed at the same amounts as the controlling-shareholder figure in each year, so no non-controlling interest gap appears.

Net cash used in operating activities rose every year, from -KRW 14.4 billion in 2022 to -KRW 25.3 billion in 2023, -KRW 28.4 billion in 2024, and -KRW 30 billion in 2025.

According to press reports, the company recorded no revenue in 2025, and fixed costs such as GMP facility upkeep, raw materials, R&D, and depreciation were incurred before any sales. On a quarterly basis, the company has posted losses for five consecutive quarters from Q3 2025 to Q3 2026.

The operating loss was KRW 9.19 billion in Q3 2025, KRW 8.71 billion in Q4 2025, KRW 7.8 billion in Q1 2026, KRW 9.74 billion in Q2 2026, and KRW 7.74 billion in Q3 2026, widening in Q2 and narrowing in Q3.

The net loss attributable to controlling shareholders in Q3 2026 was KRW 8.98 billion, narrower than both the prior quarter and the year-earlier quarter. The sum of the controlling-shareholder net losses over the last four quarters, from Q4 2025 to Q3 2026, was KRW 52.8 billion.

Press reports on Q1 2026 indicated selling, general and administrative expenses of KRW 7.8 billion, up from KRW 6.2 billion a year earlier, with R&D expenses of KRW 6.4 billion, equal to 82.4% of SG&A. Even after approval, follow-on clinical and platform development costs are weighing on earnings.

Pre-IPO estimates reportedly projected 2026 revenue of KRW 114.1 billion, but no revenue was recorded in 2025, and actual sales depend on the timing of reimbursement listing.

05

Industry analysis

Novartis's Kymriah has effectively dominated the Korean CAR-T market. Press reports put Kymriah's official price at KRW 360,039,359, and its domestic reimbursement is limited to patients after third-line treatment.

With RIMQARTO's approval, a domestically produced product may change competitive dynamics in price, supply stability, and patient access.

However, RIMQARTO's price is widely expected to be benchmarked against the weighted average price of Kymriah as the alternative drug, and the final price depends on negotiations with the National Health Insurance Service. On the supply side, Curocell highlights its domestic production base.

Press reports noted that overseas products require manufacturing facilities at Korean hospitals, which made them difficult to use at regional hub hospitals. Other Korean companies are also pursuing CAR-T indication and reimbursement expansion, so competition in Korea is gradually widening.

Technically, solid tumor CAR-T is regarded as a difficult area because of the tumor microenvironment and antigen heterogeneity, but it carries substantial market and clinical potential if successful.

In vivo CAR-T, which generates CAR-T cells inside the body, could reduce manufacturing burden, and it has drawn growing interest from global pharma and biotech companies.

In hematologic cancers, LigaChem Biosciences and other Korean companies plan to present research at the ASH annual meeting in December 2026, which gives a reference point for Korean blood cancer therapy research.

06

Outlook

The nearest checkpoint is National Health Insurance listing. RIMQARTO is in price negotiations with the National Health Insurance Service, and whether and when it is reimbursed will be decided after the negotiation outcome and review by the Health Insurance Policy Deliberation Committee.

The company targets reimbursement listing and commercial patient dosing within 2026.

The company said it was selected for a pilot program that runs approval, evaluation, and negotiation in parallel, and it has been discussing insurance coverage with the Health Insurance Review and Assessment Service since before approval.

The company plans to launch RIMQARTO immediately after price negotiations and listing, and it expects the top five large hospitals in Korea to be major customers. Indication expansion to second-line treatment depends on the change approval of the Phase 3 trial plan, which was applied for on October 30, 2026.

In hematologic cancers, long-term follow-up data from the RIMQARTO Phase 2 trial will be presented at ASH on December 12–15, 2026. The CEO said the adult ALL study will move to Phase 2 in the second half of 2026. In autoimmune disease, the systemic lupus erythematosus study began enrolling patients in 2026.

Stated uses of the funds include KRW 3.0 billion for upgrading the commercial GMP facility, with the rest allocated to solid tumor CAR-T and other pipeline R&D and operating expenses.

Overseas, the company is pursuing entry into Japan and early efficacy confirmation in solid tumors through investigator-led trials in China.

The next items to confirm are the timing of reimbursement listing and the early prescription volume after listing, and the 2026 annual report, due by March 31, 2027, will disclose full-year operating losses and cash outflow trends.

07

Valuation

PER
—
PBR
5.0×
ROE
-125.9%
EPS
-₩3,566
BPS
₩4,469
Dividend per share
₩0

Several facts matter when reading the company's valuation. Because net losses attributable to controlling shareholders have continued over the last four quarters, the price-to-earnings ratio cannot be calculated, so earnings-based multiple comparisons do not apply.

The price-to-book ratio sits in a range that reflects a large premium over net asset value, which should be read alongside total equity of KRW 5.03 billion. Total liabilities of KRW 104.7 billion against a thin equity base produce a debt-to-equity ratio of 2,083.4%, a defining feature of the balance sheet.

The company does not pay dividends, so a dividend yield comparison within the industry is not meaningful. Compared with commercial-stage peers in the sector, Curocell recorded no revenue in 2025, so the valuation framework differs.

Share price has moved sharply since approval, so the key valuation questions come down to three items: the timing of revenue, the terms of financing, and the clinical data from the pipeline.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

First domestic approval and a local production base

RIMQARTO's approval on April 29, 2026 gave the company the distinction of being the first domestically developed CAR-T therapy in Korea. Production at the Daejeon commercial GMP facility, without overseas manufacturing steps, is cited as a basis for shorter supply times.

The company says the product can be used at regional hub hospitals without their own manufacturing facilities, which could widen its customer base.

Indication and pipeline expansion

A change application for the Phase 3 trial plan for second-line treatment was submitted on October 30, 2026. Long-term Phase 2 follow-up data for RIMQARTO are scheduled for presentation at ASH in December 2026.

Solid tumor CAR-T, in vivo CAR-T, and autoimmune disease studies are running in parallel, preparing growth drivers beyond RIMQARTO.

Financing eased part of the near-term pressure

Press reports in April 2026 described convertible bonds and convertible preferred shares totaling KRW 72.7 billion. The company said it has no plans for additional fundraising. The operating loss narrowed in Q3 2026 compared with the year-earlier quarter, which may be an early sign of cost discipline after approval.

09

Bear factors

A loss-making structure without revenue

No revenue was recorded in 2025, with an operating loss of KRW 36.3 billion and net cash used in operating activities of -KRW 30 billion. Operating cash outflows grew each year from -KRW 14.4 billion in 2022. SG&A expenses in Q1 2026 rose from the prior-year period, so costs have not declined after approval.

Financial strain and a thin equity base

Press reports said liquidity at the end of Q1 2026 was KRW 16.2 billion, the current ratio fell to 36.1%, and net debt turned to KRW 19 billion. Total liabilities of KRW 104.7 billion compare with total equity of only KRW 5.03 billion. The sum of controlling-shareholder net losses over the last four quarters was KRW 52.8 billion.

Uncertainty over ultra-high pricing and reimbursement talks

Industry observers expect RIMQARTO's price to be in the KRW 300 million range, a level that makes negotiations difficult given health insurance budgets and patient cost burden. The approved indication covers third-line or later treatment, so the eligible patient pool stays limited until second-line expansion. With Kymriah holding the existing market, the pace at which new prescriptions shift is still uncertain.

10

Risk factors

Clinical, approval, and indication expansion risk

Approval for second-line treatment depends on Phase 3 results, so both the timing and the outcome are uncertain. Solid tumor and in vivo CAR-T are known to be technically demanding areas. Even with favorable long-term data, converting to actual prescriptions requires hospital operations and supply stability to line up.

Financial and funding risk

Operating losses and cash outflows continue, while convertible instruments bring repayment and conversion obligations. The KRW 72.7 billion financing reported in April 2026 strengthened short-term liquidity, but financing costs and potential share dilution remain. Analysts have said the priority of fund deployment will serve as a basis for future value assessment.

Pricing, reimbursement, and competitive risk

RIMQARTO's price is expected to be in the hundreds of millions of won, and Kymriah's weighted average price is a likely benchmark. If reimbursement listing is delayed, revenue will be pushed back even after approval.

Whether its supply-model differentiation translates into prescription growth in a market long dominated by Kymriah remains to be seen.

11

What to watch next

  1. December 12–15, 2026

    Long-term Phase 2 follow-up data for RIMQARTO will be presented at the ASH annual meeting in New Orleans. Durability of complete remission and safety data will inform the discussion on second-line expansion and overseas entry.

  2. By the end of 2026

    Whether and when reimbursement applies will be decided after the price negotiation outcome and the Health Insurance Policy Deliberation Committee review. The launch timing after listing and the early prescription pace will shape the scale of first revenue.

  3. After December 2026 (timing not set)

    This is the outcome of the change approval for the Phase 3 trial plan covering second-line treatment, which was applied for on October 30, 2026. Whether enrollment begins after approval and on what schedule will show the pace of indication expansion.

  4. By March 31, 2027

    This is the filing deadline for the 2026 annual report, which will disclose full-year 2026 operating loss, net loss attributable to controlling shareholders, and operating cash flow. The scale of the operating loss and the trend in cash outflows in that report are the next confirmation points.

12

Overall view

Curocell entered the commercialization stage after RIMQARTO, Korea's first domestically developed CAR-T therapy, received approval in April 2026, but its financial statements still show a loss-making structure with no revenue.

The company recorded losses for four consecutive years from 2022 to 2025, with a 2025 operating loss of KRW 36.3 billion and a net loss attributable to controlling shareholders of KRW 46.3 billion.

The Q3 2026 operating loss narrowed to KRW 7.74 billion from both the prior quarter and the year-earlier period, but the sum of controlling-shareholder net losses over the last four quarters was KRW 52.8 billion.

On the balance sheet, total equity of KRW 5.03 billion at the end of 2025 stands against total liabilities of KRW 104.7 billion, and press reports described Q1 2026 liquidity of KRW 16.2 billion and net debt of KRW 19 billion.

Strengths include the domestic production base, the second-line indication filing, and the solid tumor and in vivo pipeline, while weaknesses include delayed revenue, expanding cash outflows, and uncertainty over ultra-high pricing and reimbursement talks.

The nearest checkpoints are the ASH presentation in December 2026 and whether reimbursement listing is achieved within 2026, followed by operating loss and cash flow data in the 2026 annual report.

Because earnings-based multiples cannot be calculated, the timing of revenue and the terms of financing are the key variables for valuation.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. thevc.kr
  2. dailypharm.com
  3. news.nate.com
  4. pharm.edaily.co.kr
  5. pinpointnews.co.kr
  6. dailyinvest.kr
  7. curocellbtx.com
  8. news.nate.com
  9. paxetv.com
  10. newstomato.com
  11. biotimes.co.kr
  12. ebn.co.kr
  13. sisajournal-e.com
  14. news.nate.com
  15. kr.investing.com
  16. m.news.nate.com
  17. theviewers.co.kr
  18. mt.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis